| Literature DB >> 19732481 |
B Rutherford1, J Sneed, D Devanand, R Eisenstadt, S Roose.
Abstract
BACKGROUND: Response to antidepressant medication is higher in comparator versus placebo-controlled randomized controlled trials (RCTs). Patient expectancy is an important influence on clinical outcome in the treatment of depression and may explain this finding. The results are reported from a pilot RCT studying expectancy and depression outcome in placebo-controlled versus comparator treatment conditions.MethodOut-patients aged 18-65 years with major depressive disorder (MDD) were enrolled in this 8-week RCT. Subjects were randomized to placebo-controlled (escitalopram or placebo) or comparator (escitalopram or citalopram) administration of antidepressant medication. Subjects reported their expected likelihood and magnitude of depression improvement before and after randomization using questions from the Credibility and Expectancy Scale (CES). A regressed change model of post-randomization expectancy of improvement was fit to the data to determine whether subjects in the comparator group reported greater expectancies of improvement than subjects in the placebo-controlled group.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19732481 PMCID: PMC3784014 DOI: 10.1017/S0033291709991085
Source DB: PubMed Journal: Psychol Med ISSN: 0033-2917 Impact factor: 7.723